Teva Reaffirms Growth Strategy, Eyes $5 Billion Innovative Franchise By 2030 - Teva Pharmaceutical Indus (NYSE:TEVA)

Teva Reaffirms Growth Strategy, Eyes $5 Billion Innovative Franchise By 2030 - Teva Pharmaceutical Indus (NYSE:TEVA)

Israeli multinational pharmaceutical company Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) hosted 2025 Innovation & Strategy Day on Thursday to launch the acceleration phase of its “Pivot to Growth” strategy and to discuss portfolio priorities. The company outlined its plan to evolve into a leading biopharmaceutical company, emphasizing its innovative medicines franchise and a strong generics and biosimilars portfolio. President and CEO Richar…

I Hiked the Alps in Comfy Teva Sandals—and Now I’m Eyeing These 12 Similar Pairs, From $30

Wear these versatile sandals straight from the trail to the city.Travel + LeisureFlip-flop culture is part of my DNA. As an Aussie, I was basically born to wear what we call thongs 365 days a year, whether I’m at the beach, park, or pub. As a frequent traveler who now spends all her summers in Europe, I pull out all my flip-flops and sandals and romp around cities like Zurich, Berlin, and Paris in open-toe shoes as soon as the sun peeks out. But…

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

Teva outlines acceleration path into a leading biopharma companyInnovative medicines franchise on track to exceed $5 billion by 2030, led by AUSTEDO® (deutetrabenazine), AJOVY® (fremanezumab), UZEDY® (risperidone) and late-stage pipeline with blockbuster potentialReaffirming 2027 financial targets, including 30% operating profit…

Teva gives aggressive guidance for innovative drugs

The company sees revenue from its leading products doubling to $5 billion by 2030.